Roivant’s subsidiary Pulmovant reported positive Phase 2 PHocus results for mosliciguat, an inhaled treatment licensed from Bayer for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The 135-patient trial met its primary endpoint, showing a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16.
Secondary endpoints also improved:
six-minute walk distance increased by 35.2 meters and NT-proBNP, a marker of cardiac strain, fell by 53.2% versus placebo.
Mosliciguat’s cough rate was 12.1%, lower than the 18.2% reported in the placebo group, according to the reported results.
Roivant paid Bayer $14 million upfront in 2024 for worldwide rights, with up to $280 million in potential milestone payments plus royalties. The deal’s total potential value was approximately $294 million.
Pulmovant has reportedly advanced mosliciguat into Phase 3, targeting roughly 200,000 PH-ILD patients in the United States and Europe.
The results are encouraging but do not establish regulatory approval; Phase 3 data and regulatory review will still be required.
Sources:
Roivant's $14M bet on Bayer's inhaled hypertension med ...
Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med
Roivant acquires drug for pulmonary hypertension from ...
Recent News Coverage | Roivant
Roivant Sciences: Unlocking 2025 Catalysts with Vant Model and ...
Roivant sets up Pulmovant to advance hypertension therapy
Roivant unveils its next deal, hoping for TL1A-sized potential from a… | Andrew Dunn
Roivant Sciences' Strategic Position in the Evolving ...
Unveiling New Pipeline Program - Mosliciguat
Roivant Launches Pulmovant with In-Licensed Bayer Drug for ...
Pulmovant says that a Phase 2 trial of its mosliciguat DPI has ...
Roivant Unveils New Pipeline Program Mosliciguat, A Potential ...